Atlas Trials

IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.

Clinical trial NCT04933799 · UNKNOWN

Trial details

NCT number
NCT04933799
Sponsor
Giovanni Franchin, M.D, Ph.D
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
COVID-19 Pneumonia
Start date
2021-01-06
Primary completion
2022-03-06
Enrollment
68

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.